<DOC>
	<DOCNO>NCT01190761</DOCNO>
	<brief_summary>The objective study compare rate extent absorption Purepac , subsidiary Alpharma Inc. , U.S.A. , galantamine Janssen Pharmaceutica Products , L.P. , U.S.A. ( Reminyl ) , galantamine , administer 1 x 4 mg tablet , fed condition .</brief_summary>
	<brief_title>Bioequivalence Study Galantamine 4 mg Tablet Reminyl Following 4 mg Dose Healthy Subjects Under Fed Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , 2-period , 2-sequence , crossover design . Official Title : Randomized , 2-Way Crossover , Bioequivalence Study Galantamine 4 mg Tablet Reminyl Following 4 mg Dose Healthy Subjects Under Fed Conditions . Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Subjects enrol study member community large . The recruitment advertisement may use various medium type ( e.g . radio , newspaper , SFBC Anapharm Web site , SFBC Anapharm volunteer ' database ) . Subjects must meet follow criterion order include study : Male female , smoker nonsmoker , 18 year age old Capable consent . BMI2:19.0 &lt; 30.0 kg/rn '' . Subjects follow applies exclude study : â€¢ Clinically significant illness within 4 week prior administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Medical SubInvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive test hepatitis B , hepatitis C , HN screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . History significant alcohol abuse drug abuse within one year prior screen visit . Regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) . Use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction heparin , galantamine , tertiary alkaloid derivative relate drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoine , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion ofthe drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary ( include asthma COPD ) , hematologic , immunologic , psychiatric , metabolic disease . Use prescription medication ( include hormone therapy ) within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption hormonal contraceptive . Difficulty swallow study medication . Smoking 25 cigarette per day . Any food allergy , intolerance , restriction special diet , opinion Medical SubInvestigator , could contraindicate subject 's participation study . A depot injection implant drug ( hormonal contraceptive ) within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 300 mL whole blood within 30 day , 301 mL 500 mL whole blood within 45 day , 500 mL whole blood within 56 day prior drug administration . History `` sick sinus syndrome '' supraventricular cardiac conduction disorder , active coronary artery disease congestive heart failure . History unexplained syncopal episode . Consumption food beverage contain grapefruit ( e.g . fresh , can , frozen ) within 7 day prior administration study medication . History ulcer disease . History asthma obstructive pulmonary disease . History seizure disorder . Breastfeeding . Positive urine pregnancy test screening . Female subject childbearing potential unprotected sexual intercourse nonsterile male partner ( i.e . male sterilized vasectomy least 6 month ) within 14 day prior study drug administration . Acceptable method contraception : condom + spermicide ; diaphragm + spermicide ; intrauterine contraceptive device ( place least 4 week prior study drug administration ) ; hormonal contraceptive ( start least 4 week prior study drug administration ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Galantamine</keyword>
	<keyword>Reminyl</keyword>
	<keyword>Galantamine hydrobromide</keyword>
	<keyword>Healthy subject</keyword>
</DOC>